NYSE$AMRX
Amneal Pharmaceuticals Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Amneal's Q4 2022 financial results were announced, with net revenue increasing by 14% compared to the previous year. The company reported a GAAP net loss of $4 million, but adjusted net income reached $71 million. The adjusted diluted EPS was $0.23, a 35% increase from Q4 2021.
Amneal Pharmaceuticals reported a mixed Q4 2022, with increased net revenue but a net loss according to GAAP. Adjusted EBITDA and EPS showed strong growth, driven by new product launches, expansion of the AvKARE channel, and strong specialty product performance. The company provided 2023 financial guidance, expecting continued revenue and adjusted EBITDA growth.
- Net revenue for Q4 2022 was $610 million, a 14% increase year-over-year.
- GAAP net loss was $4 million, an improvement from the $6 million loss in Q4 2021.
- Adjusted EBITDA increased by 26% to $154 million.
- Adjusted diluted EPS rose by 35% to $0.23.
Headline financials
Revenue & EPS history
Amneal · Revenue · Quarterly
$610M
Revenue by segment
Amneal · $211M total across 2 segments · Q4 2022
- AvKARE$108M+20.6%51.3%
- Specialty$103M+1.5%48.7%
Forward guidance
Amneal provided its full year 2023 financial guidance, projecting net revenue between $2.25 and $2.35 billion and adjusted EBITDA between $500 and $530 million.
Tailwinds
- Net revenue between $2.25 billion and $2.35 billion
- Adjusted EBITDA between $500 million and $530 million
- Adjusted diluted EPS between $0.40 and $0.50
- Operating cash flow between $200 million and $230 million
- Capital expenditures of $50 million to $60 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-0.6%
Avg return
Earnings day
-3.2%
Avg return
5 days after
+0.4%
Avg return
30 days after
54%
20 / 37 earnings
Positive
+36.6%
Q2 2023
Best reaction
-23.0%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.7% | -7.6% | +0.9% | |
| Q4 2025 | -4.6% | -8.2% | -18.2% | |
| Q3 2025 | -4.1% | +8.8% | +20.0% | |
| Q1 2025 | +3.0% | -6.7% | -5.4% | |
| Q4 2024 | +3.5% | +7.0% | -1.2% | |
| Q3 2024 | +6.9% | +4.9% | -1.9% | |
| Q2 2024 | +12.9% | +9.6% | +21.9% | |
| Q1 2024 | +7.1% | +6.1% | +7.6% | |
| Q4 2023 | -2.2% | -3.8% | +9.8% | |
| Q3 2023 | -3.6% | +0.2% | +11.4% | |
| Q2 2023 | +36.6% | +25.9% | +25.6% | |
| Q1 2023 | +9.8% | -3.3% | +38.6% | |
| Q4 2022 | -8.1% | -15.8% | -33.5% | |
| Q3 2022 | +13.0% | +8.2% | +16.8% | |
| Q2 2022 | -9.5% | -9.2% | -36.4% | |
| Q1 2022 | -11.5% | -22.2% | -13.0% | |
| Q4 2021 | -7.0% | -12.4% | -3.4% | |
| Q3 2021 | -12.5% | -9.8% | -29.0% | |
| Q2 2021 | +4.5% | +4.9% | +6.6% | |
| Q1 2021 | -8.1% | -8.0% | -5.5% | |
| Q4 2020 | +5.9% | +0.0% | +40.1% | |
| Q3 2020 | -15.0% | -15.6% | -14.6% | |
| Q2 2020 | -16.3% | -19.9% | -30.7% | |
| Q1 2020 | +20.3% | +16.1% | +42.5% | |
| Q4 2019 | -20.4% | -16.4% | -37.0% | |
| Q3 2019 | -23.0% | -23.0% | +7.0% | |
| Q2 2019 | -8.0% | -10.5% | -18.5% | |
| Q1 2019 | -20.7% | -31.0% | -41.8% | |
| Q4 2018 | +8.4% | +2.0% | +13.8% | |
| Q3 2018 | +5.1% | +4.6% | -9.1% | |
| Q2 2018 | +0.6% | +9.8% | +19.4% | |
| Q1 2018 | +1.5% | +13.3% | +30.2% | |
| Q4 2017 | +4.4% | — | — | |
| Q3 2017 | +5.9% | — | — | |
| Q2 2017 | +1.5% | — | — | |
| Q1 2017 | -3.2% | — | — | |
| Q4 2016 | +2.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro